Chymase Inhibition Attenuates Kidney Fibrosis in a Chronic Mouse Model of Renal Ischemia–Reperfusion Injury
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26083913 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sakura Kure und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innovative Medicine, Graduate School of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki-City 569-8686, Osaka, Japan. Hauptthemen laut MEDLINE: Chymases, Reperfusion Injury, Kidney, Renal Insufficiency, Chronic. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research (C) from the Ministry of Education, Science, Sports, and Culture in Japan.
Abstract (Originalsprache)
Although various factors contribute to the transition from acute kidney injury (AKI) to chronic kidney disease (CKD), no clinically effective pharmacological treatment has been established. We investigated whether chymase inhibition is effective in preventing renal fibrosis, a key process in the transition from AKI to CKD. Male BALB/c mice were subjected to unilateral ischemia-reperfusion (I/R) injury, and TY-51469, a chymase-specific inhibitor, was administered intraperitoneally at a dose of 10 mg/kg/day for 6 weeks. The 45 min ischemic period followed by 6 weeks of reperfusion resulted in severe renal atrophy. Renal fibrosis was particularly pronounced in the transition region between the cortex and medulla in placebo-treated mice. The expression of mouse mast cell protease 4 (MMCP-4, a mouse chymase) mRNA, the number of chymase-positive mast cells, and fibrosis-related factors, such as transforming growth factor (TGF)-β1 and collagen I, were all significantly increased in I/R-injured kidneys. However, treatment with TY-51469 significantly suppressed fibrosis formation, along with the inhibition of renal chymase and TGF-β1 expression. These findings suggest that chymase inhibition may be a potential therapeutic strategy for preventing the transition from AKI to CKD by reducing fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Innovative Medicine, Graduate School of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki-City 569-8686, Osaka, Japan.
- Department of Nephrology, Osaka Medical and Pharmaceutical University, Takatsuki-City 569-8686, Osaka, Japan.
- Department of Clinical Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, 1 Misasagi Shichono-cho, Yamashina-ku 607-8412, Kyoto, Japan.
- Department of Pharmacology, Osaka Medical and Pharmaceutical University, Takatsuki-City 569-8686, Osaka, Japan.
ORCID-Profile: Hiroe Toba, Denan Jin, Shinji Takai
Förderung
- Scientific Research (C) from the Ministry of Education, Science, Sports, and Culture in Japan
Zitieren
APA
Kure, S., Toba, H., Jin, D., Mima, A., & Takai, S. (2025). Chymase Inhibition Attenuates Kidney Fibrosis in a Chronic Mouse Model of Renal Ischemia–Reperfusion Injury. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083913
Vancouver
Kure S, Toba H, Jin D, Mima A, Takai S. Chymase Inhibition Attenuates Kidney Fibrosis in a Chronic Mouse Model of Renal Ischemia–Reperfusion Injury. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083913
BibTeX
@article{Kure2025,
author = {Kure, Sakura and Toba, Hiroe and Jin, Denan and Mima, Akira and Takai, Shinji},
title = {Chymase Inhibition Attenuates Kidney Fibrosis in a Chronic Mouse Model of Renal Ischemia–Reperfusion Injury},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26083913}
}
EUVIMED